PET/MRI and the revolution of the third eye

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 10, 2012, Pages 1519-1524

  Mansi, Luigi ^a   Ciarmiello, Andrea ^b   Cuccurullo, Vincenzo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; SUPERPARAMAGNETIC IRON OXIDE;

BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CELL MEMBRANE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DOSIMETRY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HOMEOSTASIS; HUMAN; HYPOXIA; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PSYCHOPHYSIOLOGY; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE;

ANIMALS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY;

EID: 84868260708     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2185-x     Document Type: Review

References (19)

1. Bailey TM, Vealé BL. Advanced computed tomography technology and patient dose: a literature review. Radiol Manage. 2011;33 (5):43-6.
2. Fanti S, Farsad M, Mansi L. PET-CT beyond FDG. Berlin: Springer Verlag; 2010.
3. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011;41(4):265-82.
4. Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(1):46-52.
5. Arnaldi D, Morbelli S, Morrone E, Campus C, Nobili F. Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging. Q J Nucl Med Mol Imaging. 2012;1:55-67.
6. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5(5):303-24.
7. De Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology. 2007;69(20):1942-52.
8. Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging. 2009;4(1):1-23.
9. Modo M, Hoehn M, Bulte JW. Cellular MR imaging. Mol Imaging. 2005;4(3):143-64.
10. Tunariu N, Kaye SB, Desouza NM. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer. 2012;106(4):619-28.
11. Tournier JD, Mori S, Leemans A. Diffusion tensor imaging and beyond. Magn Reson Med. 2011;65(6):1532-56.
12. Abraham T, Feng J. Evolution of brain imaging instrumentation. Semin Nucl Med. 2011;41(3):202-19.
13. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging. 2011;29(5):587-600.
14. Todd-Pokropek A. Advances in computers and image processing with applications in nuclear medicine. Q J Nucl Med. 2002;46(1):62-9.
15. Israel O, Keidar Z, Iosilevsky G, Bettman L, Sachs J, Frenkel A. The fusion of anatomic and physiologic imaging in the management of patients with cancer. Semin Nucl Med. 2001;31(3):191-205.
16. Lucignani G, De Palma D. PET/CT in paediatric oncology: clinical usefulness and dosimetric concerns. Eur J Nucl Med Mol Imaging. 2011;38(1):179-84.
17. Bettinardi V, Picchio M, Di Muzio N, Gianolli L, Messa C, Gilardi MC. PET/CT for radiotherapy: image acquisition and data processing. Q J Nucl Med Mol Imaging. 2010;54(5):455-75.
18. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol. 2008;18(6):1077-86.
19. Delso G, Ziegler S. PET/MRI system design. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S86-92.